Don't have an account? Create Account
Don't have an account? Create Account
FILTER WITHIN THIS TAG ››
Action
Quality
Education
Institute
Reset
Subscribe
Loading more articles
pharmaceutical drug pricing and 340B

The final rule on drug ceiling prices and manufacturer civil monetary penalties under the 340B Drug Pricing Program now will go into effect on Oct. 1.

view more »
pharmaceutical drug pricing and 340B

CMS projects that Medicare Advantage organization payment rates will increase by 0.25 percent in 2018.

view more »
pharmaceutical drug pricing and 340B

The regulation makes "penny pricing" final and sets fines of up to $5,000 per instance of a manufacturer overcharging providers for covered medications in the 340B Drug Pricing Program.

view more »
pharmaceutical drug pricing and 340B

OIG found that the federal portion of spending on catastrophic coverage reached $33.2 billion in 2015, compared with $10.8 billion in 2010.

view more »
pharmaceutical drug pricing and 340B

In a FAQ document, CMS states that the required JW modifier and patient documentation policy applies to separately payable Part B drugs.

view more »
pharmaceutical drug pricing and 340B

Medicare Part D spending increased 17 percent, outpacing overall prescription drug spending increases, according to CMS data.

view more »
pharmaceutical drug pricing and 340B

The decision follows the pharmaceutical company's recent recalculation of 340B ceiling prices for 25 products for the third quarter of 2012 through the second quarter of 2013.

view more »
pharmaceutical drug pricing and 340B

March 8 proposed rule details two approaches agency will test to encourage prescribing of lower-cost medications: reimbursement rate adjustments and value-based purchasing.

view more »
pharmaceutical drug pricing and 340B

Proposed regulations would dramatically narrow access to 340B, harming vulnerable patients and putting entire communities at risk of losing vital services.

view more »
pharmaceutical drug pricing and 340B

Final rule and implementation as described in the guidance could significantly reduce Medicaid payments for 340B-covered outpatient drugs in some states.

view more »
pharmaceutical drug pricing and 340B

House, Senate panels to examine rising cost of drugs, lack of transparency in the drug price negotiation process, and barriers to generic drug applications.

view more »
pharmaceutical drug pricing and 340B

U.S. District Court says 2014 HRSA interpretive rule is contrary to plain language of ACA provision that excludes certain hospitals from 340B discounts on orphan drugs.

view more »
pharmaceutical drug pricing and 340B

Heritage Pharmaceuticals Inc., charged 340B covered entities incorrect rates between April 18, 2008 and Dec. 31, 2014. Refunds are available for products purchased directly from Heritage or through a wholesale distributor.

view more »
pharmaceutical drug pricing and 340B

Proposed changes could significantly narrow the scope of patients for whom 340B pricing may be utilized and reduce potential savings from program

view more »
pharmaceutical drug pricing and 340B

Omnibus guidance proposes an expanded list of six requirements for an individual to be considered a patient of a 340B covered entity.

view more »
pharmaceutical drug pricing and 340B

Participants learned about HRSA's guidance on the 340B Drug Pricing Program and how it will affect their hospital.

view more »
pharmaceutical drug pricing and 340B
pharmaceutical drug pricing and 340B

Failure to recertify will result in removal from the 340B program. Authorizing officials from all hospitals should have already received an email with information needed to recertify from the Office of Pharmacy Affairs.

view more »
pharmaceutical drug pricing and 340B

Sen. Grassley requested a hearing on recent 340B GAO report. House calls and clinical trials for Medicare patients each pass one chamber. Committees review Medicare hospital payments, HIT, and marketplaces.

view more »
pharmaceutical drug pricing and 340B

Report suggests financial incentive for hospitals to prescribe 340B drugs, a claim America's Essential Hospitals calls unfounded and troubling.

view more »
pharmaceutical drug pricing and 340B

Association challenges unfounded conclusions in report, including suggestion that hospitals overuse 340B for financial gain.

view more »
pharmaceutical drug pricing and 340B
pharmaceutical drug pricing and 340B
pharmaceutical drug pricing and 340B

The 2015 recertification period will be from Aug. 5 to Sept. 9. Failure to recertify will result in removal from the program.

view more »
pharmaceutical drug pricing and 340B

Proposed rule also calls for increased transparency in ceiling price calculation. Separate guidance to replace mega reg.

view more »
pharmaceutical drug pricing and 340B

Parts of the Cures package will now likely go to other House committees for review. The Senate will discuss NSA surveillance after recess.

view more »
pharmaceutical drug pricing and 340B

We are pleased to see that this amendment was not included in the Cures package and look forward to working with lawmakers to strengthen the 340B program in the future.

view more »
pharmaceutical drug pricing and 340B

We look forward to working with the committee and others in Congress as they seek to strengthen this valuable program and provide other support for those in need.

view more »
pharmaceutical drug pricing and 340B

Association urges committee to reject inclusion of 340B program changes in 21st Century Cures bill

view more »
pharmaceutical drug pricing and 340B

It remains unclear what 340B Drug Pricing Program provisions could be included in the legislation.

view more »
pharmaceutical drug pricing and 340B

The Energy and Commerce Committee is scheduled to vote on 21st Century Cures Wednesday, possibly including an amendment that would make changes to the 340B Drug Pricing Program.

view more »

About America’s Essential Hospitals

America’s Essential Hospitals is the leading association and champion for hospitals and health systems dedicated to high-quality care for all, including the most vulnerable. Since 1981, America’s Essential Hospitals has initiated, advanced, and preserved programs and policies that help these hospitals ensure access to care. We support members with advocacy, policy development, research, and education.